stockrow
Friday 6 November 2026
Export PEN’s income statement to Excel — free account
Penumbra, Inc.
PEN Healthcare Medical Devices
Penumbra, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 17.5% from fiscal 2024.
- Revenue
- +15.6%
- EPS
- −8.29%
- Free cash flow
- −37.2%
- Total debt
- −10.3%
Quarter to September 2026, against a year earlier
320.08
1.03
−0.32%
Follow PEN
Alert me
Penumbra, Inc. (PEN) Net income
Penumbra, Inc.'s net income for fiscal 2025 was $177.7M, up 1,168.1% from $14.0M in fiscal 2024. Over the twelve months to 30 September 2026 it was $157.0M. Over the past ten years it has ranged from −$19.3M (fiscal 2020) to $177.7M (fiscal 2025) — the current reading is the highest in ten years. Penumbra, Inc. ranks 17th of 149 Medical Devices companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | $177.7M | 1,168.11% |
| FY2024 | $14.0M | (84.59%) |
| FY2023 | $91.0M | — |
| FY2022 | −$2.0M | — |
| FY2021 | $2.6M | — |
| FY2020 | −$19.3M | — |
| FY2019 | $47.0M | 1,515.26% |
| FY2018 | $2.9M | (37.51%) |
| FY2017 | $4.7M | (68.56%) |
| FY2016 | $14.8M | 526.38% |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | $42.3M | 21.45% |
| Jun 2026 | $34.8M | 6.83% |
| Mar 2026 | $32.6M | (31.17%) |
| Dec 2025 | $47.3M | 3.25% |
| 43 more quarters | Free account |
Against its own ten years
Low −$19.3M
High $177.7M
Ten-year median
$4.7M
Current reading's percentile
100
Net income against peers
| Company | Net income |
|---|---|
| SNN Smith & Nephew SNATS, Inc. compare | $2.0B |
| BIO.B Bio-Rad Laboratories, Inc. compare | $616.6M |
| BIO Bio-Rad Laboratories, Inc. compare | $616.6M |
| GMED Globus Medical, Inc. compare | $557.6M |
| PODD Insulet Corporation compare | $428.8M |
| PEN Penumbra, Inc. | $157.0M |
| TXG 10x Genomics compare | −$75.1M |
| BRKR Bruker Corporation compare | −$115.7M |
| GKOS Glaukos Corporation compare | −$169.8M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on PEN
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement